Team:Ciencias-UNAM/Achievements

From 2013.igem.org

(Difference between revisions)
(Created page with "<html> <head> <title>Achievements</title> <meta http-equiv="content-type" content="text/html; charset=utf-8"/> <meta http-equiv="imagetoolbar" content="no"/> <meta name="app...")
 
(5 intermediate revisions not shown)
Line 389: Line 389:
<div id="u47" class="u47" >
<div id="u47" class="u47" >
-
<div id="u47_rtf"><p style="text-align:left;"><span style="font-family:Arial;font-size:20px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">Achievements</span></p><p align="justify">
+
<div id="u47_rtf"><p style="text-align:left;"><span style="font-family:Arial;font-size:20px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">Achievements</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"> Please visit our <b><a href="https://igem.org/2013_Judging_Form?id=1230">Judging Form</a> </b>
-
<p><span style="font-family:Arial;font-size:14px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">Do the biological materials used in your lab work pose any of the following risks?</span></p>
+
-
<span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to the safety and health of team members or others working in the lab?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"> No the lab is a regular educational and basic investigation laboratory.
+
-
</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to the safety and health of the general public, if released by design or by accident?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"> No, as all the strains are non-pathogenic if there was a release of them it would not cause any harm. Also the sequences used for the design are from other non-pathogenic strains and the product of them are not harmful separately or the construction itself.
+
-
</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to the environment, if released by design or by accident?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">The possible risk for the environment would be against pathogenic strains due our design. Nevertheless, considering the probabilities for our design to be expressed outside laboratory conditions, we do not think there would be any risk to the environment.
+
-
</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to security through malicious misuse by individuals, groups, or countries?
+
-
</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">The device itself does not contain any harmful DNA sequence, and as our strains are non-pathogenic ones could not be used for malicious misuse.
+
-
</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:14px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">As our device is meant against pathogenic strains if it would become an industrial Project. We should first analyze the possible risks for being used in humans</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:14px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">What safety training have you received (or plan to receive in the future)? and under what biosafety provisions will / do you work? </span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">Our formation about safety comes from working in laboratories with a BioSafety level number 1, if we may work in the future in a laboratory with a different BioSafety level then we should get trained. The UNAM School of Science follows the biosafety regulations from the UNAM and in particular the recommendations made by the Environmental Management Unit. A more detailed protocol can be found at <b>(www.biomedicas.unam.mx/_administracion/_unidades_apoyo_inst/ manual_bioseguridad.pdf)</b>. Mexican regulations about biosafety are summarized at <b>http://amexbio.org/links.html</b>  According to WHO Biosafety manual our lab and our chassis is rated as Biosafety level 1.
+
-
<br><br>
+
-
The part is the human cathelicidin LL-37. The part is the BBa_K1230001 ( http://parts.igem.org/Part:BBa_K1230001). The human peptide LL-37 is a cationic antimicrobial peptide with activity against Gram-negative and Gram-positive bacteria. It has been shown to protect against Helicobacter pylori infection and its related gastritis, besides of inhibiting the growth of other pathogenic bacteria in the gastrointestinal tract such as Salmonella typhimurium and Escherichia coli.
+
-
We are using it because we want our synthetic bacteria to express the LL-37 antimicrobial peptide in presence of pathogenic bacteria that express quorum sensing molecule AI-2.
+
-
<br><br>
+
-
There is no potential safety/health risk for the team members, institution staff or general public by using the part that codes for de LL-37 antimicrobial peptide because is a human gene that is express only when the inmmune system interacts with a pathogenic microbe like Helicobacter pylori.
+
-
<br><br
+
-
The part is NOT listed under the Australia Group guidelines. The safety level of the lab was the BSL1 as the the strains and the coding regions used are non pathogenic and non potentially phatogenical when transcribed by our chassis organism.
+
-
</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p></div>
+
 +
<br><b>Requirements for a Bronze Medal:</b>
 +
<br>Register the team, have a great summer, and plan to have fun at the Regional Jamboree.
 +
<br>Successfully complete and submit this iGEM 2013 Judging form.
 +
<br>Create and share a Description of the team's project using the iGEM wiki and the team's parts using the Registry of Standard Biological Parts.
 +
<br>Plan to present a Poster and Talk at the iGEM Jamboree.
 +
<br>Document at least one new standard BioBrick Part or Device used in your project/central to your project and submit this part to the iGEM Registry (submissions must adhere to the iGEM Registry guidelines).
 +
<br>https://2013.igem.org/Team:Ciencias-UNAM/Project/WetLab/BioBricks
 +
 +
<br><br><b>Additional Requirements for a Silver Medal:</b>
 +
<br>Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected.
 +
<br>Document the characterization of this part in the 'Main Page' of that Part's/Device's Registry entry
 +
<br>Submit this new part to the iGEM Parts Registry (submissions must adhere to the iGEM Registry guidelines)
 +
<br>Part Number(s): BBa_K1230004, “MarA Generator”
 +
<br>http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230004
 +
<br>Your project may have implications for the environment, security, safety and ethics and/or ownership and sharing. Describe one or more ways in which these or other broader implications have been taken into consideration in the design and execution of your project.
 +
 +
<br><br><b>Additional Requirements for a Gold Medal:</b>
 +
<br>Improve the function of an existing BioBrick Part or Device (created by another team or your own institution in a previous year), enter this information in the 'Experience' section of that Parts's Registry entry), create a new registry page for the improved part, and submit this part to the iGEM Registry (submissions must adhere to the iGEM Registry guidelines).
 +
<br>Part Number(s): BBa_K1230007, “araC-pBad-rbs-LL37”
 +
<br>http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230007
 +
<br>Outline and detail a new approach to an issue of Human Practice in synthetic biology as it relates to your project, such as safety, security, ethics, or ownership, sharing, and innovation.
 +
<br>We did formal Petition to Mexican Congress to review DNA import/export politics, addressing a letter to Congressman Rúben Benjamín Félix Hays, President of the Science and Technology Commission of the Mexican Congress, given that in Mexico the Federal Commission for Protection against Health Risks (COFEPRIS), regulates, with a lot of normative has flaws, both imports and export of genetic material for research. These flaws make genetic material imports unavailable for very large periods of time.  Noting the urge of creating a law initiative in this matter and proposing changes in the already existing norms, we take in account aspects such as security, ethics, and above all, the aspect of sharing.
 +
<br>
 +
<br><b>Best BioBrick Measurement Approach: </b>
 +
<br>Our experiments focused on the measurements of the expected phenotypes, which in our case, involve the increase or decrease of viability or inhibition. To measure the experiment in this way is relevant, since the expected function of the part is a phenotype. Although measuring via reporters is useful to infere the production of a certain protein, the cuatitiative measure of the effect is more relevant in parts like ours. The designed experiments allow to use two variables (in this case the induction with IPTG and the concentration of antibiotic) and to show not only the characterization of a promoter (as it is often done) but also a cuantitative measure of the desired phenotype.
 +
 +
<br><b>Best Model:</b> We were able to recognize parameters based on the system dynamics.
 +
 +
<br><b>Team_Parts</b>
 +
<br>Best new BioBrick Part, Natural:
 +
<br>Part Number(s): BBa_K1230000, “AcrAB-TolC multidrug efflux transport system activator from E. coli”
 +
<br>http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230000
 +
<br>Best new BioBrick Part or Device, Engineered:
 +
<br>Part Number(s): BBa_K1230004, “MarA Generator”
 +
<br>http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230004
 +
 +
<br><b>Most Improved Registry Part:</b>
 +
<br><br><i>Part Number(s):</i> BBa_K1230007, “araC-pBad-rbs-LL37”
 +
<br><br><i>Short description of improvements made to the part:</i>
 +
<br><br>We characterised LL-37 antimicrobial peptide from Team Trieste 2008. They used Lac promoter to express this peptide, hoping to inhibit cell growth. They did not have positive results, as the control experiment growth the same way as the one with LL-37 expression with IPTG. We approached this problem with two solutions. The first problem we saw in Trieste's characterisation was that Lac promoter has a very high basal level of transcription. Given pSB1C3 has a high copy number, it is transcribing a high amount of LL-37, still with no IPTG in the media. This could mean that there is selection pressure on E. coli to loose the plasmid, which could be one of the reasons the did not see changes between the control cells and the cells under IPTG induction. We addressed this problem by changing the promoter, constructing device BBa_K1230007. This device is under the pBad promoter, which works with arabinose. This promoter has a basal level of almost 0, so we are sure that it is not transcribing any LL-37 that could be making the cells to loose the plasmid. The second problem we addressed was the change in the codon usage they used. By changing the codons to produce more peptide in E. coli, the peptide may not have sufficient time to fold properly, altering it's function. We solved this problem by using the normal codon usage of this peptide, allowing it to fold properly into it's final conformation.
 +
<br><br><b>Best Part Collection:</b> (give the range of part numbers)
 +
<br><br><i>Part Number(s): </i>BBa_K1230000, BBa_K1230001, BBa_K1230004, BBa_K1230007, BBa_K1230009, BBa_K1230010, BBa_K1230011, BBa_K1230013, BBa_K1230015, BBa_K12300016 not found
 +
<br><br><i>Short description of collection function:</i>
 +
<br><br>As part of our collection, we also designed the device BBa_K1230009, which is the promoter as well as the coding sequence for the repressor AraC which is transcribed in the opposite direction, with the Elowitz repressilator. This part will allow an easy way to produce proteins by Arabinose induction, improving the way characterization is made on iGEM.
 +
 +
</span></p>
</div>
</div>

Latest revision as of 04:18, 28 September 2013

Achievements

HOME

PROJECT

HUMAN PRACTICES

TEAM

ACHIEVEMENTS

Home > Achievements

Achievements

Please visit our Judging Form
Requirements for a Bronze Medal:
Register the team, have a great summer, and plan to have fun at the Regional Jamboree.
Successfully complete and submit this iGEM 2013 Judging form.
Create and share a Description of the team's project using the iGEM wiki and the team's parts using the Registry of Standard Biological Parts.
Plan to present a Poster and Talk at the iGEM Jamboree.
Document at least one new standard BioBrick Part or Device used in your project/central to your project and submit this part to the iGEM Registry (submissions must adhere to the iGEM Registry guidelines).
https://2013.igem.org/Team:Ciencias-UNAM/Project/WetLab/BioBricks

Additional Requirements for a Silver Medal:
Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected.
Document the characterization of this part in the 'Main Page' of that Part's/Device's Registry entry
Submit this new part to the iGEM Parts Registry (submissions must adhere to the iGEM Registry guidelines)
Part Number(s): BBa_K1230004, “MarA Generator”
http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230004
Your project may have implications for the environment, security, safety and ethics and/or ownership and sharing. Describe one or more ways in which these or other broader implications have been taken into consideration in the design and execution of your project.

Additional Requirements for a Gold Medal:
Improve the function of an existing BioBrick Part or Device (created by another team or your own institution in a previous year), enter this information in the 'Experience' section of that Parts's Registry entry), create a new registry page for the improved part, and submit this part to the iGEM Registry (submissions must adhere to the iGEM Registry guidelines).
Part Number(s): BBa_K1230007, “araC-pBad-rbs-LL37”
http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230007
Outline and detail a new approach to an issue of Human Practice in synthetic biology as it relates to your project, such as safety, security, ethics, or ownership, sharing, and innovation.
We did formal Petition to Mexican Congress to review DNA import/export politics, addressing a letter to Congressman Rúben Benjamín Félix Hays, President of the Science and Technology Commission of the Mexican Congress, given that in Mexico the Federal Commission for Protection against Health Risks (COFEPRIS), regulates, with a lot of normative has flaws, both imports and export of genetic material for research. These flaws make genetic material imports unavailable for very large periods of time. Noting the urge of creating a law initiative in this matter and proposing changes in the already existing norms, we take in account aspects such as security, ethics, and above all, the aspect of sharing.

Best BioBrick Measurement Approach:
Our experiments focused on the measurements of the expected phenotypes, which in our case, involve the increase or decrease of viability or inhibition. To measure the experiment in this way is relevant, since the expected function of the part is a phenotype. Although measuring via reporters is useful to infere the production of a certain protein, the cuatitiative measure of the effect is more relevant in parts like ours. The designed experiments allow to use two variables (in this case the induction with IPTG and the concentration of antibiotic) and to show not only the characterization of a promoter (as it is often done) but also a cuantitative measure of the desired phenotype.
Best Model: We were able to recognize parameters based on the system dynamics.
Team_Parts
Best new BioBrick Part, Natural:
Part Number(s): BBa_K1230000, “AcrAB-TolC multidrug efflux transport system activator from E. coli”
http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230000
Best new BioBrick Part or Device, Engineered:
Part Number(s): BBa_K1230004, “MarA Generator”
http://parts.igem.org/wiki/index.php?title=Part:BBa_K1230004
Most Improved Registry Part:

Part Number(s): BBa_K1230007, “araC-pBad-rbs-LL37”

Short description of improvements made to the part:

We characterised LL-37 antimicrobial peptide from Team Trieste 2008. They used Lac promoter to express this peptide, hoping to inhibit cell growth. They did not have positive results, as the control experiment growth the same way as the one with LL-37 expression with IPTG. We approached this problem with two solutions. The first problem we saw in Trieste's characterisation was that Lac promoter has a very high basal level of transcription. Given pSB1C3 has a high copy number, it is transcribing a high amount of LL-37, still with no IPTG in the media. This could mean that there is selection pressure on E. coli to loose the plasmid, which could be one of the reasons the did not see changes between the control cells and the cells under IPTG induction. We addressed this problem by changing the promoter, constructing device BBa_K1230007. This device is under the pBad promoter, which works with arabinose. This promoter has a basal level of almost 0, so we are sure that it is not transcribing any LL-37 that could be making the cells to loose the plasmid. The second problem we addressed was the change in the codon usage they used. By changing the codons to produce more peptide in E. coli, the peptide may not have sufficient time to fold properly, altering it's function. We solved this problem by using the normal codon usage of this peptide, allowing it to fold properly into it's final conformation.

Best Part Collection: (give the range of part numbers)

Part Number(s): BBa_K1230000, BBa_K1230001, BBa_K1230004, BBa_K1230007, BBa_K1230009, BBa_K1230010, BBa_K1230011, BBa_K1230013, BBa_K1230015, BBa_K12300016 not found

Short description of collection function:

As part of our collection, we also designed the device BBa_K1230009, which is the promoter as well as the coding sequence for the repressor AraC which is transcribed in the opposite direction, with the Elowitz repressilator. This part will allow an easy way to produce proteins by Arabinose induction, improving the way characterization is made on iGEM.